8-KOther Events

BRISTOL MYERS SQUIBB CO 8-K Report (Mar 31, 2004)

Filed March 31, 2004For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) filed an 8-K on March 31, 2004, to announce significant developments related to its product Paraplatin® and a patent appeal. The company issued a press release on March 31, 2004, detailing these events. Key information for investors includes the status of the pediatric submission for Paraplatin® and a favorable reversal by a federal appeals court concerning a patent. These updates are critical for understanding the company's product pipeline, potential market exclusivity, and ongoing legal strategies that could impact future revenues and profitability.

Key Highlights

  • 1BMY filed an 8-K on March 31, 2004, to report an event occurring on March 30, 2004.
  • 2The filing incorporates by reference a press release issued on March 31, 2004.
  • 3The press release discusses the registrant's statement regarding the Paraplatin® pediatric submission.
  • 4The press release also covers a federal appeals court reversal on a patent.
  • 5The company's principal executive office is located at 345 Park Avenue, New York, NY 10154.
  • 6No financial statements or pro forma financial information are included in this specific filing, as it pertains to 'Other Events'.

Frequently Asked Questions

The press release discussed two key matters: the status of Bristol-Myers Squibb's pediatric submission for its drug Paraplatin® and a federal appeals court's reversal of a decision related to a patent.

Pediatric submissions often relate to seeking expanded indications or market exclusivity for a drug when used in children. Investors would be interested in this to understand potential market growth and regulatory approvals.

A favorable patent reversal by an appeals court can be very significant. It could mean that a competitor's product might be blocked from entering the market, or that Bristol-Myers Squibb's own patent protection is strengthened, potentially securing market exclusivity and future revenue streams.

No, this particular 8-K filing is designated under 'Item 5. Other Events' and 'Item 7. Financial Statements and Exhibits,' specifically referencing a press release. It does not contain financial statements or pro forma financial information itself.